TBX21: A Drug Target / Disease Biomarker (G30009)

Target Name: TBX21

NCBI ID: G30009

TBX21: A Drug Target / Disease Biomarker

TBX21 is a protein that is expressed in various tissues throughout the body, including the lungs, heart, kidneys, and intestines. It is a member of the T-cell bombardment protein (TBP) family, which is known for their role in cell signaling and cancer progression.

One of the key functions of TBX21 is its role in the development and progression of cancer. It has been shown to be involved in the regulation of cell proliferation, differentiation, and survival. In addition, TBX21 has also been shown to play a role in the regulation of immune cell function, which is important for both cancer and normal immune system function.

Given its potential involvement in cancer progression and immune system function, TBX21 has been identified as a potential drug target. Researchers are currently working to develop small molecules and other compounds that can inhibit the activity of TBX21 and prevent its development and progression. These compounds have the potential to be used as both anti-cancer agents and immune system regulators.

In addition to its potential use as a drug, TBX21 has also been identified as a potential biomarker for cancer. Its expression has been shown to be elevated in a variety of cancer types, including lung, breast, and colorectal cancers. This suggests that TBX21 may be a useful diagnostic marker for these cancers, as well as for other diseases where its expression is increased.

Overall, TBX21 is a protein that has the potential to be a drug target or biomarker for a variety of diseases. Further research is needed to fully understand its role in cell signaling and cancer progression, as well as its potential as a drug and biomarker.

Protein Name: T-box Transcription Factor 21

Functions: Lineage-defining transcription factor which initiates Th1 lineage development from naive Th precursor cells both by activating Th1 genetic programs and by repressing the opposing Th2 and Th17 genetic programs (PubMed:10761931). Activates transcription of a set of genes important for Th1 cell function, including those encoding IFN-gamma and the chemokine receptor CXCR3. Induces permissive chromatin accessibilty and CpG methylation in IFNG (PubMed:33296702). Activates IFNG and CXCR3 genes in part by recruiting chromatin remodeling complexes including KDM6B, a SMARCA4-containing SWI/SNF-complex, and an H3K4me2-methyltransferase complex to their promoters and all of these complexes serve to establish a more permissive chromatin state conducive with transcriptional activation (By similarity). Can activate Th1 genes also via recruitment of Mediator complex and P-TEFb (composed of CDK9 and CCNT1/cyclin-T1) in the form of the super elongation complex (SEC) to super-enhancers and associated genes in activated Th1 cells (PubMed:27292648). Inhibits the Th17 cell lineage commitment by blocking RUNX1-mediated transactivation of Th17 cell-specific transcriptinal regulator RORC. Inhibits the Th2 cell lineage commitment by suppressing the production of Th2 cytokines, such as IL-4, IL-5, and IL- 13, via repression of transcriptional regulators GATA3 and NFATC2. Protects Th1 cells from amplifying aberrant type-I IFN response in an IFN-gamma abundant microenvironment by acting as a repressor of type-I IFN transcription factors and type-I IFN-stimulated genes. Acts as a regulator of antiviral B-cell responses; controls chronic viral infection by promoting the antiviral antibody IgG2a isotype switching and via regulation of a broad antiviral gene expression program (By similarity). Required for the correct development of natural killer (NK) and mucosal-associated invariant T (MAIT) cells (PubMed:33296702)

More Common Targets